Clinical characteristics of digestive system cancers metastatic to the heart.
10.3760/cma.j.cn112152-20210824-00637
- Author:
Jia Lin TANG
1
;
Bo ZHANG
1
;
Xing Yuan WANG
1
;
Yan SONG
1
;
Jian Ping XU
1
;
Tao QU
1
;
Yihebali CHI
1
;
Jing HUANG
1
Author Information
1. Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
- Publication Type:Journal Article
- Keywords:
Cardiac metastasis;
Clinical features;
Digestive system neoplasms;
Pericardial metastasis
- MeSH:
Humans;
Esophageal Neoplasms/pathology*;
Retrospective Studies;
Prognosis;
Esophageal Squamous Cell Carcinoma;
Digestive System Neoplasms/drug therapy*;
Gastrointestinal Neoplasms
- From:
Chinese Journal of Oncology
2022;44(11):1229-1232
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the clinical features of patients with cardiac metastases from digestive system tumors. Methods: This retrospective study collected and analyzed the medical records of patients with cardiac metastases from digestive system tumors who received treatments in the Cancer Hospital, Chinese Academy of Medical Sciences between January 1999 and January 2021. Kaplan-Meier method was used for survival analysis. Results: A total of 19 patients were identified. The primary tumors were esophageal squamous cell carcinoma (n=7), gastric or gastroesophageal junction adenocarcinoma (n=6), hepatobiliary cancers (n=3) and colorectal cancers (n=3). 16 patients had pericardial metastases, 2 patients had right atrium metastases, and 1 patient had left ventricle metastasis. The most common symptom was dyspnea, which was present in 8 cases. 7 patients received locoregional treatment, while 11 patients underwent systemic therapies. The median overall survival from diagnosis of primary cancer was 31.4 months, and the median overall survival time from diagnosis of cardiac metastasis was 4.7 months. Conclusion: Cardiac metastasis from digestive system tumors is associated with low incidence and a poor prognosis. Systemic treatment remains the cornerstone of management, while novel anti-tumor drugs may improve therapeutic efficacy.
